AstraZeneca's AI drug discovery deal with insitro
Why it matters
AstraZeneca pays insitro $40M upfront, with up to ~$1.46B in potential milestones plus single-digit royalties, to apply insitro's Virtual Human AI platform to MASH (a metabolic liver disease) and cardiomyopathies, where one diagnosis spans patients with different underlying biology. insitro takes AstraZeneca-nominated targets to development candidate; AstraZeneca leads trials and commercialization with exclusive worldwide rights to selected programs. Fine print: under 3% of the ~$1.5B headline is upfront, and the work starts at target discovery.
Read the source: AstraZeneca (opens in a new tab)
All hits from 19 Oct 2026More BusinessGet the daily hits by email